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We used a xenograft model to investigate whether the aryl hydrocarbon receptor deletion construct
CD553 suppresses tumor growth. HeLa cells that were infected with CD553 expressing adenovirus
(Ad553) formed very small tumors whereas the control adenovirus-infected cells formed large
tumors at day 15. CD553 inhibited the formation of the HIF-1 DNA complex and suppressed the
induction of the HIF-1a target proteins CAIX and GLUT1. The Ad553 tumors had less HIF-1 function
since they showed reduced microvessel formation and lesser amounts of HIF-1a, Arnt, phospho-Akt,
CAIX, and GLUT1. Proteasome-mediated Arnt degradation was enhanced in Ad553-infected HeLa
cells and tumors.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hypoxia inducible factor-1 (HIF-1) plays a pivotal role in our
compensatory response to the low cellular oxygen content in local-
ized tissues. HIF-1 is a heterodimeric transcription factor consist-
ing of HIF-1a and Arnt (HIF-1b) that regulates the expression of
a battery of target genes related to glucose metabolism and angio-
genesis [1]. In the case of solid tumors, the hypoxic core stabilizes
the HIF-1a protein which is responsible for more efﬁcient glucose
metabolism in cancers. Other than control of the HIF-1a function
at the protein level, HIF-1a transcription is regulated via the Akt
pathway [2] and phosphorylation of HIF-1a by MAPKs p42/p44
[3] and ERK [4] appears to affect its transcriptional activity, reveal-
ing other means cancer cells may control the HIF-1a function un-
der normoxia. Cancers that overexpressed HIF-1a have a poor
prognosis [5,6] and inhibition of HIF-1a after ionizing irradiation
appears to be a rational approach for chemotherapy [7].
The aryl hydrocarbon receptor (AhR) is a well-known xenobi-
otic responsive transcription factor which regulates a battery of
gene transcription most notably the phase I and II drug metaboliz-
ing enzymes [8]. Since Arnt is a mutual partner of AhR and HIF-1a,
we had proposed that there may be crosstalk between these two
pathways and had demonstrated that indeed crosstalk exists be-
tween AhR and HIF-1a [9]. In principle, if there is an AhR-like mol-
ecule interacting with most of the nuclear Arnt protein, HIF-1achemical Societies. Published by Esignaling may be inhibited. We tested out this hypothesis by utiliz-
ing the human AhR construct CD553 (amino acid 1–295) which
contains the DRE and Arnt binding domains but not the ligand
binding domain because 553 amino acids are deleted from the C-
terminus. We reported that CD553 suppresses the CoCl2-driven
luciferase and HIF-1 target gene expression in MCF-7 cells [10].
In this paper, we showed that CD553 inhibits xenograft tumor
growth and the mechanism of inhibition is consistent with the
inhibition of the HIF-1 signaling in xenograft tumors.2. Materials and methods
2.1. Reagents
HeLa cells were cultured in DMEM (Sigma) supplemented with
10% FBS (Tissue Biologicals), 100 units/ml of penicillin, 0.1 mg/ml
of streptomycin and 2 mM glutaMAX. Gel shift probes were pur-
chased from Invitrogen as follows: HRE (OL105, 50-GCCCTAC-
GTGCTGTCTCA-30; OL106, TGAGACAGCACGTAGGGC-30); mutated
HRE (OL107, 50-GCCCTAATTGCTGTCTCA-30; OL108, TGAGA-
CAGCAATTAGGGC-30). Adenovirus Ad553 and AdLacZ generation
is described under the Supplementary data.
2.2. Xenograft tumor model
Animal experiments were carried out in accordance with the
guidelines of NIH animal use (NIH publication number 85-23)
and of the University of the Paciﬁc. When HeLa cells were 80%lsevier B.V. All rights reserved.
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stock of Ad553 or AdLacZ or PBS was added to the cells (see Sup-
plementary data for virus generation). After 72 h at 37 C, cells
were harvested, washed with PBS, and subjected to centrifugation
at 1000g for 5 min at 4 C. Cells were resuspended in cold PBS and
5  106 cells (100 ll) were injected subcutaneously to each of two
lower back sites of a 6–8-week-old female homozygous athymic
nude mouse (Simonsen Lab). Tumors were measured two to three
times a week, and the tumor volume was calculated as a  b2  0.5,
where a and b were large and small diameters, respectively. Mice
were sacriﬁced after 2–3 weeks when tumors were close to
2 cm3 and the tumor weights were then measured.
2.3. Western blot analysis
After SDS–PAGE, proteins were transferred onto a nitrocellulose
membrane using Bio-Rad mini Trans-Blot cell for 1.5 h at 4 C. Pri-
mary antibody was incubated overnight at 4 C. SuperSignal West
Pico HRP chemiluminescent substrate (Thermo Scientiﬁc) was
used to detect the signals. Antibodies used: anti-HIF-1a IgG 07-
628 (Millipore), anti-Arnt IgG H172 (Santa Cruz), anti-CAIX IgG
H-120 (Santa Cruz), anti-GLUT1 IgG ab652 (Abcam), anti-phos-
pho-Akt S473 IgG 9277 (Cell Signaling), and anti-GAPDH IgG
G9549 (Sigma), anti-AhR IgG H-211 to detect AhR (Santa Cruz),
and anti-AhR IgG N19 to detect CD553 (Santa Cruz). N19 was not
used to detect AhR because it shows a non-speciﬁc band very close
to AhR and 10 times higher antibody amount is necessary to detect
AhR when compared with H-211. H-211 cannot detect CD553
since H-211 was raised against the AhR C-terminal 211 amino
acids which are absent in CD553.
2.4. Gel shift assay
HeLa cells were grown under various conditions in a 75 cm2
ﬂask. Nuclear extracts were obtained (see Supplementary data)
and were immediately diluted to a ﬁnal concentration of 0.1 M
KCl. Three micrograms of nuclear extract was incubated with
2 lg of poly-dIdC, 100 ng of calf thymus DNA, and 40 ng of mu-
tated HRE for 15 min at room temperature. 32P-Labelled HRE probe
(100 000 cpm) was added to each sample. After 15 min at room
temperature, samples were separated on a 4% native acrylamide
gel at 4 C and the dried gel was analyzed.
2.5. Statistical analysis
Unpaired two-tailed t test was performed using the Prism 5
software.Fig. 1. (A) Western blot showing CD553 expression in HeLa cells after adenoviral infecti
AdLacZ or Ad553 was added and then harvested after 72 h. Fifty micrograms of high salt
100 ll of PBS (WT), high titer Ad553 or AdLacZ. CellTiter-Glo reagent (Promega) was use
numbers at the 12 h were arbitrarily set to 1 for normalization. Error bars represent ±S.D.
between Ad553 and AdLacZ at 72 h is not statistically signiﬁcant.3. Results
3.1. CD553 does not directly suppress HeLa cell growth
When we infected HeLa cells with the high titer Ad553 virus, an
abundant amount of CD553 was expressed 3 days after infection
(Fig. 1A). We examined whether expression of CD553 would have
any direct effect on the HeLa cell growth. We seeded
1.5  104 cells/well in a 96-well plate in the presence or absence
of adenovirus and then followed the cell growth for 3 days. Wild-
type cells showed proportionate growth from 12 to 60 h and then
leveled off up to 72 h because cells were approaching 100% conﬂu-
ency at 60 h (Fig. 1B). When cells were infected with adenovirus,
regardless of Ad553 or AdLacZ, cells proliferated faster from 12
to 36 h, leveled off from 36 to 60 h, and then cell death occurred
from 60 to 72 h. The increased cell growth and the eventual cell
death were caused by adenoviral infection but not a CD553 effect,
since Ad553 and AdLacZ showed the same pattern. We observed a
slight increase of cell proliferation at 36 h when compared the
Ad553-infected cells with the AdLacZ-treated cells.
3.2. Ad553 suppresses HeLa xenograft growth
We examined whether HeLa cells expressing CD553 would in-
hibit tumor formation in nude mice. To rule out the general aden-
oviral effect, AdLacZ-infected HeLa cells were used to develop
tumor. Uninfected and AdLacZ-infected HeLa cells formed tumors
readily in nude mice; however, there was substantial difference
in tumor size at day 14 when cells were infected with Ad553 prior
to injection (Fig. 2A). The wild-type cells showed signiﬁcant tumor
growth at day 7 (548 mm3 ± 92) and the tumor continued to grow
up to 1572 mm3 ± 403 at day 14 (Fig. 2B). But the Ad553-infected
HeLa cells formed only a small tumor: the tumor size was <5% of
the AdLacZ tumor at day 14 (57 mm3 ± 28 and 1208 mm3 ± 484
for Ad553 and AdLacZ tumors, respectively). At the time of harvest
(day 15), the weights of wild-type, Ad553, and AdLacZ tumors were
580 mg ± 68, 32 mg ± 13, and 459 mg ± 150, respectively (Fig. 2C).
3.3. Ad553-infected HeLa tumors have less HIF-1 function
Most of the Ad553 tumors were too small to be excised for anal-
ysis. Nonetheless, we were able to obtain a few Ad553 tumors to
perform Western analysis, which showed that protein levels of
HIF-1a and Arnt were signiﬁcantly less in Ad553 tumors but were
present in the control (wild-type and AdLacZ) tumors (Fig. 3). In
addition, the HIF-1a target proteins CAIX and GLUT1 were also sig-
niﬁcantly less in Ad553 tumors when compared with the controlon. Cells (4  106) were seeded in a 75 cm2 ﬂask. After 24 h, 100 ll of PBS, high titer
extract was loaded per lane. (B) Time-dependent growth of HeLa cells treated with
d to quantify cell numbers at various time points (12, 24, 36, 48, 60 and 72 h). The
of triplicate values. * represents P < 0.0024 when compared with WT. The difference
Fig. 2. Xenograft tumor growth. HeLa cells were treated with 100 ll of PBS, high
titer Ad553 or AdLacZ for 3 days before injection into nude mice. (A) Tumor
appearance at day 14 of nude mice injected with Ad553-infected (left), AdLacZ-
infected (middle) or uninfected wild-type (right) HeLa cells. (B) Graph showing
time-dependent tumor growth in size (mm3). Error bars represent ±S.D. for n = 6.
(C) Graph showing the tumor weight at time of harvest (day 15). Error bars
represent ±S.D. for n = 6. This xenograft experiment was repeated two more times
with similar results. * represents P < 0.0005; n.s. represents not signiﬁcant.
Fig. 3. Western analysis of tumor samples showing different protein expression in
Ad553 tumors. (A) Lanes 1 and 2 are high salt extracts from HeLa cells ±200 lM
CoCl2 treatment for 24 h. Lanes 3–5 are high salt extracts from the Ad553-infected,
AdLacZ-infected and wild-type (WT) tumors. Each lane contained 50 lg of protein.
p-Akt represents phospho-Akt S473.
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mors. Immunohistochemical staining data showed that CAIX and
GLUT1 were expressed in control tumors but minimal, if any, in
Ad553 tumors (Fig. 4). Staining using CD31 antibody showed that
microvessels were more apparent in the control tumors than in
Ad553 tumors. Interestingly, Akt was phosphorylated in control tu-
mors but was noticeably less phosphorylated in Ad553 tumors
(Figs. 3 and 4).
3.4. CD553 promotes Arnt degradation via the ubiquitin-proteasome
pathway and reduces the amount of the HIF-1a/Arnt/HRE complex
formation
Protein levels of both HIF-1a and AhR were less in CoCl2-treated
HeLa cells in the presence of Ad553 or AdLacZ, suggesting that
reduction of these protein levels was caused by adenoviral infec-
tion, not a CD553 effect (Fig. 5A and B). Interestingly, the Arnt con-
tent was pronouncedly reduced at the Ad553 dose we used to
infect HeLa cells before injection (Fig. 5A, lane 10). This reductionof the cellular Arnt level was inversely proportional to the amount
of the CD553 protein present. AdLacZ did not cause any change of
the Arnt content, suggesting that CD553 reduced the nuclear Arnt
content in HeLa cells. We further explored whether CD553 might
affect the Arnt degradation using the proteasome inhibitor
MG132. We observed that MG132 prevented the lowering of the
Arnt content, suggesting that the proteasome-mediated Arnt deg-
radation was triggered by CD553 (Fig. 5C). Additionally, the
CD553 protein was also degraded by the 26S proteasome. Next,
we examined whether the amount of HIF-1 formation in the HeLa
nuclear extract could be reduced in the presence of CD553 by gel
shift assay. We observed that the intensities of the HIF-1 com-
plexes were reduced by CD553 in a dose-dependent manner
(Fig. 5D) and this reduction was not caused by the AdLacZ control.
The identities of the HIF-1 complexes were conﬁrmed by using
cold oligonucleotides: cold HRE abolished the HIF-1 complexes
whereas an equal amount of mutated HRE did not. Interestingly,
we observed two HIF-1 complexes which were shown by another
group as well [11]. The upper complex appeared to be more sensi-
tive to wild-type HRE than the lower complex.
4. Discussion
Many researchers have successfully blocked the HIF-1a func-
tion based on our current knowledge of how HIF-1 signals. A dom-
inant-negative HIF-1a construct presumably competes with HIF-
1a for Arnt binding and in turn inhibits the HIF-1 transcriptional
activity [12] and suppresses tumor growth [7]. Similarly, an HIF-
1a splice variant inhibits the HIF-1a function by interacting with
Arnt [13]. The interaction surface between HIF-1a and its coactiva-
tor p300 appears to be a good target for inhibiting the HIF-1a activ-
ity [14]. Although the Arnt content in cell lines seems abundant
[15], the Arnt-dependent function should be blocked if we can
somehow sequester the nuclear Arnt protein. We predicted that
when adequate (large) amount of CD553 is present in the cell nu-
cleus, it should heterodimerize with Arnt and physically limit Arnt
Fig. 4. Immunohistochemical staining showing reduced microvessel formation and altered protein expression in Ad553 tumors. Protocol can be found in Supplementary
data. Xenograft tumors from mice injected with wild-type (WT) HeLa cells or cells infected with AdLacZ or Ad553 were sectioned and immunohistochemical staining was
performed using NBT/BCIP (purple/blue). Representative images are shown at original magniﬁcation 10 (CD31) or 50 (phospho-Akt S473 (p-Akt), GLUT1, and CAIX).
Nuclear fast red stain shows the nuclei in p-Akt, GLUT1, and CAIX.
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amount of CD553 indeed inhibits the HIF-1 function.
There are opposing arguments on the effect of HIF-1a inhibition
on tumor growth. In most solid tumors, overexpression of HIF-1a
is a hallmark for tumor development; however, some researchers
observed the contradicting results in the case of head and neck
squamous cell carcinoma [16] and lung cancer [17]. HIF-1a is
essential for tumor growth in nude mice because the inhibition
of the xenograft tumor growth was observed when (1) the HIF-
1a content was suppressed by RNA interference [18] and (2) the
HIF-1 function was inhibited by an N-terminal HIF-1a dominant-
negative construct [7]. Nonetheless, it is widely known that tumors
typically rely more on glycolysis to produce ATP for survival and
HIF-1a promotes higher amount of ATP production through glycol-
ysis [19]. Many of the glycolytic enzymes and proteins involved in
glucose transport are induced by HIF-1a; therefore, blockade of the
HIF-1a function should limit ATP production and suppress tumor
growth. Results from our xenograft experiments clearly showed
that HeLa cells that expressed an abundant amount of CD553 lost
their capability of developing into a tumor. CAIX and GLUT1 were
expressed in much lesser extent in Ad553 tumors, which was con-
sistent with our prediction that HIF-1a function was suppressed in
the presence of CD553.
Since CD553 interferes with the HIF-1a and AhR function [10],
we examine whether the protein levels of Arnt, HIF-1a and AhR
could be altered in response to the CD553/Arnt interaction. Sur-
prisingly the Arnt content, which is normally quite stable, was
drastically reduced in the Ad553 tumors, as compared with the
wild-type and AdLacZ tumors. In contrast, the lesser amount of
AhR in Ad553 tumors appeared to be an adenoviral effect since Ad-LacZ caused a similar reduction. The Arnt content in Ad553-in-
fected HeLa cells at the time of injection was already reduced
and the Arnt content remained low in Ad553 tumors at day 15.
We were only able to detect CD553 in HeLa cells before injection
but not in Ad553 tumors. Therefore, the effect of CD553 on the
suppression of tumor growth is likely to occur at the onset of tu-
mor growth and the sustained presence of CD553 is not required
for the low Arnt content observed in the Ad553 tumors. Our data
clearly showed that HIF-1a protein accumulation was inhibited
in Ad553 tumors, although this inhibition was not observed in
Ad553-infected HeLa cells. It is unclear how HIF-1a is induced in
HeLa xenografts and whether the sustained low Arnt content in
Ad553 tumors is a cause or an effect of the tumor suppression.
Regardless, the proteasome-mediated degradation of Arnt is
clearly triggered in Ad553-infected HeLa cells. More studies are
necessary to explore the mechanism of the CD553 effect at play
in these tumors.
Reduction of the phospho-Akt content by Ad553 is intriguing.
Activation of the PI3K/Akt pathway increases the HIF-1a protein
content via mechanisms involving transcriptional control [20]
and Hsp70/Hsp90-dependent HIF-1a protein accumulation [21].
Sphingosine kinase 1 activates phosphorylation of Akt at serine
473 and in turn phosphorylates GSK3b, which is responsible for
HIF-1a protein accumulation via a pVHL-mediated mechanism
[22]. Interestingly, phospho-Akt is reduced in the AhR null mouse
mammary ﬁbroblasts which cause xenograft tumor growth [23].
Although suppression of phospho-Akt content by Ad553 might
contribute to the disappearance of HIF-1a and relate to the inhibi-
tion of the AhR function in Ad553 tumors, the picture seems to be
much more complex. Highest phospho-Akt content was consis-
Fig. 5. Effect of CD553 on HIF-1 signaling. HeLa cells were grown in a 75 cm2 ﬂask infected with Ad553 (A) or AdLacZ (B) for 48 h at 37 C. After that, they were treated
±200 lM CoCl2 for 24 h at 37 C. Lanes 1 and 2, no CoCl2, no adenovirus; lanes 3-10, increasing amounts of Ad553 or AdLacZ treatment (20–100 ll of high titer virus). Each
lane contained 50 lg of protein. p-Akt, phospho-Akt S473; C, cytoplasmic extract; N, nuclear extract. (C) Western blot showing the Arnt and CD553 contents in Ad553-
infected HeLa cells ±5 lM MG132 treatment. Cells were infected with high titer Ad553 (20 ll) in a 6-well plate for 1-3 days and MG132 or DMSO was added 24 h before
harvest. At harvest, SDS–PAGE sample buffer was added directly into each well and then analyzed. Protein levels are normalized by GAPDH. (D) Gel shift data showing dose-
dependent suppression of the HIF-1 complex formation using HeLa nuclear extracts. Lanes 1 and 2 show CoCl2-dependent HIF1 gel shift complexes. Lanes 3–8 show the effect
on HIF-1 complexes with an increasing amount (20, 50, 100 ll of high titer virus) of AdLacZ (lanes 3–5) or Ad553 (lanes 6–8) for 3 days. Lanes 1, 9–15 show the speciﬁcity of
HIF-1 complexes. In each sample, either cold mutated HRE (mHRE) or cold wild-type HRE (wtHRE) was added. 1X represents 40 ng. The two arrows indicate the two HIF-1
complexes containing HIF-1a/Arnt/32P-HRE.
D. Wang et al. / FEBS Letters 583 (2009) 3039–3044 3043tently observed in uninfected wild-type HeLa cells where there
was no HIF-1a expression, suggesting that accumulation of the
HIF-1a protein in HeLa cells could not be explained solely by the
phospho-Akt action. Certainly CD553 might reduce the potential
AhR action in angiogenesis during tumor growth [24]. More studies
are necessary to elucidate the mechanisms for the CD553-medi-
ated tumor suppression.
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